{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_e4kvovaib22lt7fuoula","seq":1779081,"kind":"article","title":"Foghorn Drops FHD-909 Development After Phase 1, Shifts Focus To Proprietary Pipeline","url":"https://www.rttnews.com/3696352/foghorn-drops-fhd-909-development-after-phase-1-shifts-focus-to-proprietary-pipeline.aspx","published":"2026-10-05T06:36:00Z","seen":"2026-10-05T06:53:20Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q1320847","name":"foghorn","type":"org"}],"story":"st_e4kvovaib22lt7fuoula","category":"economy-business","category_p":0.66,"category2":"science-technology","sentiment":"neutral","tone":-0.05,"political":0.09},{"id":"n_36ogvpfxkeyscrqou4nq","seq":1386639,"kind":"article","title":"Lilly, Foghorn part ways; Wave's FDA-approved plans","url":"https://www.biopharmadive.com/news/foghorn-eli-lilly-wave-samsung-bioepis-teva-varda-hatteras/831918","published":"2026-10-02T16:25:34Z","seen":"2026-10-02T16:25:34Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["science","economy","business","security"],"authors":["Gwendolyn Wu"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q1320847","name":"foghorn","type":"org"},{"id":"Q262304","name":"Wave","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_36ogvpfxkeyscrqou4nq","category":"arts-culture-entertainment","category_p":0.24,"sentiment":"neutral","tone":0.07,"political":0.06},{"id":"n_a5w453lqkiddgowgw4oq","seq":1379609,"kind":"article","title":"Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ)","url":"https://seekingalpha.com/news/4649834-foghorn-downgraded-td-cowen-lilly-exit","published":"2026-10-02T14:08:00Z","seen":"2026-10-02T15:36:52Z","lang":"en","source":{"id":"seekingalpha.com","name":"seekingalpha.com","domain":"seekingalpha.com","outlet":{"wikidata":"Q3477676","name":"Seeking Alpha","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q1320847","name":"foghorn","type":"org"},{"id":"Q16952393","name":"TD Cowen","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q104481160","name":"Foghorn Therapeutics (United States)","type":"other"},{"id":"Q82059","name":"Nasdaq","type":"org"}],"story":"st_l4sstps4bhkcxry5o4bq","category":"economy-business","category_p":0.64,"sentiment":"neutral","tone":-0.16,"political":0.06},{"id":"n_4ii6je2bewyqxccvenwa","seq":1240262,"kind":"article","title":"릴리와 손잡아도 신약은 어렵다…포그혼, 개발 중단에 40% 감원","title_en":"Even with Lilly, a new drug is difficult... Foghorn, development halted, 40% layoffs","url":"https://www.medipana.com/news/articleView.html?idxno=418647","summary":"포그혼 테라퓨틱스가 일라이 릴리와 공동개발하던 항암제 프로그램을 중단하고 직원 약 40%를 감축한다. 임상 1상 자료를 검토한 뒤 후속 개발을 확대하지 않기로 결정하면서, 자체 보유 후보물질에 자원을 집중하는 방향으로 연구개발 전략을 재편한다. 미국 바이오기업 포그혼 테라퓨틱스(Foghorn Therapeutics)는 1일(현지시간) 빅파마 릴리와 함께 개발 중인 \\'FHD-909(LY4050784)\\'를 임상 개발 확대 단계로 진행하지 않기로 했다고 밝혔다. 이번 결정은 임상 1상 용량증량 시험에서 확보한 자료를 검토한 결과다. 양사","published":"2026-10-01T23:48:36Z","seen":"2026-10-02T00:25:40Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q1320847","name":"foghorn","type":"org"}],"story":"st_4ii6je2bewyqxccvenwa","category":"economy-business","category_p":0.52,"category2":"health","sentiment":"negative","tone":-0.39,"political":0.09}]}